LOS ANGELES, CA / ACCESSWIRE / December 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

If you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your ...

On Friday, Humacyte Inc (HUMA) stock saw a modest uptick, ending the day at $4.47 which represents a slight increase of $0.07 or 1.59% from the prior close of $4.4. The stock opened at $4.44 and ...

Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) has been assigned a consensus rating of “Buy” from the eight research firms ...

Class Action, Consumer Services, GlobeNewswire, Law & Legal Issues | NEW YORK, Nov. 30, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law F ...

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers ...

Investors suffering losses on their Humacyte investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 215-638-4847 or by email ...

Humacyte (HUMA) has disclosed a new risk, in the Share Price & Shareholder Rights category. Humacyte is facing substantial ...

DURHAM, N.C., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable ...

Insider activity at Humacyte (HUMA) has drawn attention after a 17% drop in the company’s stock price over the past year. Insiders, including founder Laura Niklason and board member Gordon ...

When I first analyzed Humacyte in October 2022, its stock was trading at ~$4.65 a share and prospects looked encouraging for its then dubbed human acellular vessel (HAV) platform candidates.